FGFR3 and cholangiocarcinoma: Receptor activation can also occur following DNA rearrangements; this includes juxtaposition of FGFR3 with the IGH regulatory region in multiple myeloma due to a t(4:14) translocation [10], generation of FGFR fusion proteins including FGFR3–TACC3 in glioblastoma [11], bladder [12] and other tumour types, and FGFR2 fusions with several partners in cholangiocarcinoma [13] (reviewed in [2]).